glp 1 renal benefits glp-1-based therapy GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and Trial suggests GLP-1 combo therapy – GLP-1 receptor agonists are increasingly

Updated 2015

Acknowledgements This research was funded by the Swedish Research Council (20142945 to KPS and 20137107 to PR), Novo Nordisk Foundation Excellence project grant (to KPS), Ragnar Sderberg Foundation (to KPS), Harald Jeanssons Stiftelse and Greta Jeanssons Stiftelse (to KPS), Magnus Bergvalls Stiftelse (to KPS), Wallenberg Foundation and Center for Molecular and Translational Medicine (to KPS) and National Institute of Health NIH-DK096139 (to MRH) and NIH-DK104897 (to SEK)

We also work with Freedom Diagnostics , an independent third-party testing facility, to support our quality assurance efforts

Longer-acting formulations with monthly dosing aim to reduce treatment burden and improve adherence